Bispecific antibodies in cancer immunotherapy
Following the clinical success of immune checkpoint antibodies targeting CTLA-4, PD-1 or PD-L1 in cancer treatment, bispecific antibodies are now emerging as a growing class of immunotherapies with potential to further improve clinical efficacy and safety. We describe three classes of immunotherapeu...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2018-02-01
|
| Series: | Therapeutic Advances in Vaccines and Immunotherapy |
| Online Access: | https://doi.org/10.1177/2515135518763280 |